Lindera Obtusiloba for Non-small Cell Lung Cancer
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.
Non Small Cell Lung Cancer
DIETARY_SUPPLEMENT: Lindera obtusiloba extract
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), Change from baseline to 6-week and 8-week|EORTC QLQ-LC13, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), Change from baseline to 6-week and 8-week
NK cell percentage in peripheral blood, Change from baseline to 8-week|CD4+/CD8+ T cell in peripheral blood, Change from baseline to 8-week|total T cell, T-helper cell, T-suppressor cell and B-cell percentage in peripheral blood, Change from baseline to 8-week
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.